dc.contributor.author | Hwang, A | |
dc.contributor.author | Hayden, P | |
dc.contributor.author | Pawlyn, C | |
dc.contributor.author | McLornan, D | |
dc.contributor.author | Garderet, L | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2024-05-20T11:30:26Z | |
dc.date.available | 2024-05-20T11:30:26Z | |
dc.date.issued | 2024-04-01 | |
dc.identifier.citation | British Journal of Haematology, 2024, 204 (4), pp. 1159 - 1175 | |
dc.identifier.issn | 0007-1048 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/6239 | |
dc.identifier.eissn | 1365-2141 | |
dc.identifier.eissn | 1365-2141 | |
dc.identifier.doi | 10.1111/bjh.19353 | |
dc.identifier.doi | 10.1111/bjh.19353 | |
dc.description.abstract | Recent treatment advancements in multiple myeloma have led to significant improvements in patient outcomes. Maintenance therapy following autologous haematopoietic stem cell transplantation (AHCT) is now standard of care and has been demonstrated to prolong and deepen treatment responses. Currently, lenalidomide remains the single agent that has been approved for maintenance post-AHCT in Europe and the USA which, if tolerated, is continued until disease progression. The treatment landscape is rapidly expanding however, and the optimal personalised maintenance approach for a patient is becoming more complex. Treatment outcomes for patients with high-risk disease remain poor and choice of maintenance in this population also remains unclear. This review article evaluates up-to-date literature regarding established maintenance approaches. It further analyses ongoing studies exploring maintenance regimens using combination and novel agents, approaches to maintenance in patients with cytogenetic high-risk disease and minimal residual disease response-adapted strategies that reflect the current evolving treatment paradigm. | |
dc.format | Print-Electronic | |
dc.format.extent | 1159 - 1175 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | WILEY | |
dc.relation.ispartof | British Journal of Haematology | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0 | |
dc.subject | BMT | |
dc.subject | maintenance therapy | |
dc.subject | multiple myeloma | |
dc.subject | myeloma therapy | |
dc.subject | stem cell transplantation | |
dc.subject | Humans | |
dc.subject | Multiple Myeloma | |
dc.subject | Hematopoietic Stem Cell Transplantation | |
dc.subject | Transplantation, Autologous | |
dc.subject | Lenalidomide | |
dc.subject | Treatment Outcome | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject | Stem Cell Transplantation | |
dc.title | The role of maintenance therapy following autologous stem cell transplantation in newly diagnosed multiple myeloma: Considerations on behalf of the Chronic Malignancies Working Party of the EBMT. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2024-02-12 | |
dc.date.updated | 2024-05-20T11:29:56Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1111/bjh.19353 | |
rioxxterms.licenseref.startdate | 2024-04-01 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/38390784 | |
pubs.issue | 4 | |
pubs.organisational-group | ICR | |
pubs.organisational-group | ICR/Primary Group | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Myeloma Biology and Therapeutics | |
pubs.organisational-group | ICR/Students | |
pubs.organisational-group | ICR/Students/PhD and MPhil | |
pubs.organisational-group | ICR/Students/PhD and MPhil/13/14 Starting Cohort | |
pubs.publication-status | Published | |
pubs.publisher-url | http://dx.doi.org/10.1111/bjh.19353 | |
pubs.volume | 204 | |
icr.researchteam | Myeloma Biol Therap | |
dc.contributor.icrauthor | Pawlyn, Charlotte | |
icr.provenance | Deposited by Mr Arek Surman (impersonating Prof Ros Eeles) on 2024-05-20. Deposit type is initial. No. of files: 1. Files: Br J Haematol - 2024 - Hwang - The role of maintenance therapy following autologous stem cell transplantation in newly.pdf | |